Nikiforow, S., Whangbo, J. S., Reshef, R., Tsai, D. E., Bunin, N., Abu-Arja, R., Mahadeo, K. M., Weng, W.-K., Van Besien, K., Loeb, D., Nasta, S. D., Nemecek, E. R., Zhao, W., Sun, Y., Galderisi, F., Wahlstrom, J., Mehta, A., Gamelin, L., Dinavahi, R., & Prockop, S. (2024). Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Advances, 8(12), 3001–3012. https://doi.org/10.1182/bloodadvances.2023011626

Mahadeo, K. M., Baiocchi, R., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Duan, X., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Navarro, W. H., Nikiforow, S., O’Reilly, R. J., Reshef, R., Ruiz, F., Spindler, T., & Prockop, S. (2024). Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. The Lancet Oncology, 25(3), 376–387. https://doi.org/10.1016/s1470-2045(23)00649-6

Gordon, E. R., Kwinta, B. D., Schreidah, C. M., Fahmy, L. M., Adeuyan, O., Queen, D., Trager, M. H., Magro, C. M., & Geskin, L. J. (2023). Cutaneous lymphoproliferative disorders after COVID-19 vaccination: clinical presentation, histopathology, and outcomes. Leukemia & Lymphoma, 65(1), 48–54. https://doi.org/10.1080/10428194.2023.2270766

Ford, M., Orlando, E., & Amengual, J. E. (2023). EBV Reactivation and Lymphomagenesis: More Questions than Answers. Current Hematologic Malignancy Reports, 18(6), 226–233. https://doi.org/10.1007/s11899-023-00708-5

Afify, Z. A. M., Taj, M. M., Orjuela‐Grimm, M., Srivatsa, K., Miller, T. P., Edington, H. J., Dalal, M., Robles, J., Ford, J. B., Ehrhardt, M. J., Ureda, T. J., Rubinstein, J. D., McCormack, S., Rivers, J. M., Chisholm, K. M., Kavanaugh, M. K., Bukowinski, A. J., Friehling, E. D., Ford, M. C., … Mason, C. C. (2022). Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders. Cancer, 129(5), 780–789. Portico. https://doi.org/10.1002/cncr.34600

Afify, Z., Orjuela‐Grimm, M., Smith, C. M., Dalal, M., Ford, J. B., Pillai, P., Robles, J. M., Reddy, S., McCormack, S., Ehrhardt, M. J., Ureda, T., Alperstein, W., Edington, H., Miller, T. P., Rubinstein, J. D., Kavanaugh, M., Bukowinski, A. J., Friehling, E., Rivers, J. M., … Mason, C. C. (2022). Burkitt lymphoma after solid‐organ transplant: Treatment and outcomes in the paediatric PTLD collaborative. British Journal of Haematology, 200(3), 297–305. Portico. https://doi.org/10.1111/bjh.18498

Patel, C., Pasciolla, M., Abramova, R., Salerno, D., Gomez-Arteaga, A., Shore, T. B., Orfali, N., Mayer, S., Hsu, J., Phillips, A. A., Chaekal, O.-K., Satlin, M. J., Soave, R., Kodiyanplakkal, R. P. L., Drelick, A., Plate, M., & Besien, K. V. (2023). Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients. Transplantation and Cellular Therapy, 29(2), 132.e1-132.e5. https://doi.org/10.1016/j.jtct.2022.10.023

El-Atoum, B., Williams, M., Molina, K., Orjuela-Grimm, M. A., Prince, J., & Afify, Z. (2021). Burkitt Lymphoma After Cardiac Transplantation: Therapeutic Considerations. Journal of Pediatric Hematology/Oncology, 44(3), 100–102. https://doi.org/10.1097/mph.0000000000002260